Navigation und Service

Zielgruppeneinstiege

Hinweis zur Verwendung von Cookies

Mit dem Klick auf "Erlauben" erklären Sie sich damit einverstanden, dass wir Ihren Aufenthalt auf der Seite anonymisiert aufzeichnen. Die Auswertungen enthalten keine personenbezogenen Daten und werden ausschließlich zur Analyse, Pflege und Verbesserung unseres Internetauftritts eingesetzt. Weitere Informationen zum Datenschutz erhalten Sie über den folgenden Link: Datenschutz

OK

Abstract zur Publikation: Seroprevalence of herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2) in former East and West Germany, 1997-1998

Hellenbrand W, Thierfelder W, Muller-Pebody B, Hamouda O, Breuer T (2005): Seroprevalence of herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2) in former East and West Germany, 1997-1998
Eur. J. Clin. Microbiol. Infect. Dis. 24 (2): 131-135, Feb 4, Epub ahead of print.

  • The aim of this study was to investigate the seroprevalence of herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2) in representative samples of the total former East German (FEG) and total former West German (FWG) populations. Type-specific testing with the HSV-1 (gG1) and HSV-2 (gG2) indirect ELISA was performed on an age- and sex-stratified random subsample of 3,792 sera collected during the 1997-1998 German National Health Survey. Weighted seroprevalence estimates were calculated for the total FEG and FWG populations. The overall age-standardised seroprevalence of HSV-1 was 82.6% in Germany, 85.5% (95%CI, 83.4-87.3%) in FEG and 81.8% (95%CI, 79.9-83.6%) in FWG. The overall seroprevalence of HSV-2 was 13.3% (95%CI, 11.8-14.9) in Germany, 16.5% (95%CI, 14.1-18.9) in FEG and 12.6% (95%CI, 10.7-14.5%) in FWG. The difference between FEG and FWG was largely due to the significantly higher age-adjusted seroprevalence of HSV-1 and HSV-2 in women (but not men) in FEG as compared to FWG. The HSV seroprevalence estimates in this study are consistent with results of previous less representative seroprevalence studies in Germany. Differences in HSV-2 seroprevalence between FEG and FWG suggest differences in sexual behaviour that warrant further investigation.

Zusatzinformationen

Gesundheits­monitoring

In­fek­ti­ons­schutz

Forschung

Kom­mis­sio­nen

Ser­vice

Das Robert Koch-Institut ist ein Bundesinstitut im Geschäftsbereich des Bundesministeriums für Gesundheit

© Robert Koch-Institut

Alle Rechte vorbehalten, soweit nicht ausdrücklich anders vermerkt.